Business Context and Reporting Period
Company: REGENXBIO Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 26, 2017
Event: Exercise of underwriters' option to purchase additional shares in a public offering of common stock.
Key Financial Metrics
- Additional Shares Issued: 555,000 shares of common stock.
- Aggregate Net Proceeds: Approximately $81.5 million (after deducting underwriting discounts, commissions, and estimated offering expenses).
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the increase in capital raised through the full exercise of the underwriters' option on the public offering that initially closed on March 27, 2017. This action increased the total net proceeds to the Company to approximately $81.5 million.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the completion of the share purchase option exercise and references a press release (Exhibit 99.1) for further details.
Guidance and Risks: The filing text does not provide specific forward-looking guidance, risk factors, or contingencies beyond the transaction details.
Investor Verification Checklist
- Verify the final number of shares outstanding post-transaction.
- Confirm the exact amount of underwriting discounts and offering expenses deducted to reach the $81.5 million net figure.
- Review the full press release (Exhibit 99.1) for details on the intended use of proceeds.
- Check subsequent filings for the actual cash balance impact on the balance sheet.